The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.
The company is developing a platform for synthesizing biomedical knowledge from scientific, regulatory, and commercial literature.
The firm said it will use the funds to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer.
The funding will help Mobidiag scale up production of its Novodiag instruments and disposable cartridges, and improve its global sales and marketing activities.
The company intends to use the funds to support submission of its NGS assay to the FDA, adoption of its testing by more health systems, and continued R&D.
The financing round will support Grail's ongoing development and validation of early cancer detection products.
The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.
The company had to halt and later restart billing for its cancer risk assessment tests as it transitioned to a new billing process.
The startup plans to harness single-cell genomics and computational analysis to discover therapies for autoimmune disease and cancer.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.